# Inflammatix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inflammatix

- Industry: Medical Devices & Equipment
- Headquarters: Sunnyvale, US
- Website: www.inflammatix.com/
- Total disclosed funding: $191M
- Latest round: Series E (Sep 12, 2024)
- Investors on record: 10

## About

Based in California, US, and founded in 2016 by co-founders Timothy Sweeney, Ph.D. (CEO), Purvesh Khatri, Ph.D., and Jonathan Romanowsky, Inflammatix, Inc. operates as a provider of immune system-based diagnostic tests to assist healthcare professionals in determining the presence and severity of infections or sepsis in patients requiring emergency care. In September 2024, Inflammatix, Inc. raised USD 57 million in Series E funding co-led by Khosla Ventures and Think.Health Ventures, with participation from OSF Ventures, D1 Capital Partners, Northpond Ventures, Raw Ventures, Vesalius Biocapital, and Iberis Capital.

The company provides a wide range of diagnostic solutions, such as the TriVerity Acute Infection and Sepsis Test, which helps physicians distinguish between bacterial and viral infections and evaluate the need for ICU-level interventions. Further, the firm also provides advanced bioinformatics services leveraging machine learning and artificial intelligence for improved clinical decision-making. Additionally, the company also develops products such as the Myrna device, focusing on improving clinical decision-making through advanced immune response analysis.

The company plans to use its proceeds from September 2024 funding to facilitate early commercialization of its flagship product called TriVerity and regulatory filing.

## Funding rounds

- Series E, Sep 12, 2024, $57M — Khosla Ventures, Vesalius Biocapital, OSF Ventures, Think.Health Ventures, D1 Capital Partners, Iberis Capital, Northpond Ventures, Raw Ventures
- Series D, Mar 15, 2021, $102M — Khosla Ventures, OSF Ventures, Think.Health Ventures, D1 Capital Partners, Northpond Ventures
- Series C, Jan 9, 2020, $32M — Khosla Ventures, Grey Sky Venture Partners, Think.Health Ventures, Northpond Ventures
- Series B, Oct 18, 2018 — Think.Health Ventures, Northpond Ventures
- Series A, Mar 17, 2017 — Khosla Ventures, Stanford-StartX Fund

## Investors

- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Series A, Series C, Series D, Series E
- Stanford-StartX Fund — Series A
- Think.Health Ventures (https://capitalatlas.ai/funds/think-health-ventures) — Series B, Series C, Series D, Series E
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series B, Series C, Series D, Series E
- Grey Sky Venture Partners (https://capitalatlas.ai/funds/grey-sky-venture-partners) — Series C
- OSF Ventures (https://capitalatlas.ai/funds/osf-ventures) — Series D, Series E
- D1 Capital Partners (https://capitalatlas.ai/funds/d1-capital-partners) — Series D, Series E
- Vesalius Biocapital (https://capitalatlas.ai/funds/vesalius-biocapital) — Series E
- Iberis Capital (https://capitalatlas.ai/funds/iberis-capital) — Series E
- Raw Ventures (https://capitalatlas.ai/funds/raw-ventures) — Series E